Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tempest Therapeutics (TPST)
NASDAQ:TPST
RESEARCH TOOLSreports
Holding TPST?
Track your performance easily
TPST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.17 - $9.77
Previous Close$1.45
Volume274.63K
Average Volume (3M)3.01M
Market Cap
$34.28M
Enterprise Value$25.71M
Total Cash (Recent Filing)$31.10M
Total Debt (Recent Filing)$20.25M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Nov 06, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.61
Shares Outstanding25,207,792
10 Day Avg. Volume330,184
30 Day Avg. Volume3,007,838
Standard Deviation1.64
R-Squared0.00340
Alpha0.15
Financial Highlights & Ratios
Price to Book (P/B)1.66
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.86
Forecast
1Y Price Target
$22.67Price Target Upside1566.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Tempest Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical DataThe data demonstrate a sustained and superior clinical profile for the amezalpat triplet compared to standard of care.
Clinical TrialsTempest provided critical visibility to the Street regarding the pivotal path forward for amezalpat (TPST-1120) for the treatment of first-line HCC.
Pipeline ProgressTempest continued to progress its pipeline, with a positive survival data update from its lead clinical program evaluating amezalpat in 1L HCC, with the updated results demonstrating robust clinical benefit.
Bears Say
Cash PositionThe company ended 2Q24 with $39.2 million cash.
Financial PerformanceThe company ended 2Q24 with $39.2 million cash.
Funding ConcernsShares could continue to see a broad overhang until the funding path to the Phase 3 is solved.
---
Ownership Overview
82.83% Insiders
1.56% Mutual Funds
2.04% Other Institutional Investors
13.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TPST FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $0.17 and its highest was $9.77 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Currently, no data Available
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is Nov 06, 2024 which is in 47 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on Aug 08, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.403 by -$0.017.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Undervalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate is -$0.33.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 25,207,792 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.403. Following the earnings report the stock price went down -14.179%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in TPST
---
Tempest Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.67 (1566.91% Upside)
$22.67 (1566.91% Upside)
Blogger Sentiment
Bullish
TPST Sentiment 90%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $966.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
190.00%
12-Months-Change
Fundamentals
Return on Equity
-289.26%
Trailing 12-Months
Asset Growth
37.17%
Trailing 12-Months
Company Description
Tempest Therapeutics
Tempest Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to treat cancer.
---
TPST Stock 12 Month Forecast
Average Price Target
$22.67
▲(1566.91% Upside)
Technical Analysis
Best Analysts Covering TPST
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+37.52%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +37.52% per trade.
---